| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201603721TASG10201603721TA (en) | 2016-05-10 | 2016-05-10 | Anti-CTLA-4 Antibodies |
| US16/099,652US11267887B2 (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 antibodies |
| SG11201809857TASG11201809857TA (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 Antibodies |
| EP17718870.3AEP3455255B1 (en) | 2016-05-10 | 2017-04-13 | Anti-ctla-4 antibodies |
| US15/486,468US9758583B2 (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 antibodies |
| PCT/EP2017/058956WO2017194265A1 (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 Antibodies |
| JP2018559329AJP6650537B2 (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 antibody |
| KR1020187035791AKR20190015715A (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 antibody |
| TW106112375ATW201739763A (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 antibodies |
| AU2017262448AAU2017262448A1 (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 antibodies |
| CA3023787ACA3023787A1 (en) | 2016-05-10 | 2017-04-13 | Anti-ctla-4 antibodies |
| CN201780029330.5ACN109563165B (en) | 2016-05-10 | 2017-04-13 | anti-CTLA-4 antibodies |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201603721TASG10201603721TA (en) | 2016-05-10 | 2016-05-10 | Anti-CTLA-4 Antibodies |
| Publication Number | Publication Date |
|---|---|
| SG10201603721TAtrue SG10201603721TA (en) | 2017-12-28 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201603721TASG10201603721TA (en) | 2016-05-10 | 2016-05-10 | Anti-CTLA-4 Antibodies |
| SG11201809857TASG11201809857TA (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 Antibodies |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809857TASG11201809857TA (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 Antibodies |
| Country | Link |
|---|---|
| US (2) | US11267887B2 (en) |
| EP (1) | EP3455255B1 (en) |
| JP (1) | JP6650537B2 (en) |
| KR (1) | KR20190015715A (en) |
| CN (1) | CN109563165B (en) |
| AU (1) | AU2017262448A1 (en) |
| CA (1) | CA3023787A1 (en) |
| SG (2) | SG10201603721TA (en) |
| TW (1) | TW201739763A (en) |
| WO (1) | WO2017194265A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356163B (en) | 2011-12-01 | 2018-05-16 | Chemocentryx Inc | Substituted anilines as ccr(4) antagonists. |
| EP3729967A1 (en) | 2015-05-06 | 2020-10-28 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| ES2803655T3 (en) | 2015-05-29 | 2021-01-28 | Agenus Inc | Anti-ctla-4 antibodies and methods of using them |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| SG10201603721TA (en)* | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| FI3551660T3 (en) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
| CN111511762B (en) | 2017-08-21 | 2025-05-06 | 天演药业公司 | Anti-CD137 molecules and their uses |
| CN111406069B (en)* | 2017-09-21 | 2022-12-30 | 祐和医药科技(北京)有限公司 | anti-CTLA 4 antibodies and uses thereof |
| EP3707162A1 (en) | 2017-11-10 | 2020-09-16 | Agency for Science, Technology and Research | Il2rbeta/common gamma chain antibodies |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| EP3752170A4 (en)* | 2018-02-12 | 2022-03-30 | The General Hospital Corporation | CHIMERA ANTIGEN RECEPTOR T-CELLS TARGETED AGAINST THE TUMOR MICRO ENVIRONMENT |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| AU2019269628A1 (en)* | 2018-05-17 | 2020-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| CN112601526A (en) | 2018-08-29 | 2021-04-02 | 凯莫森特里克斯股份有限公司 | Combination therapy using C-C chemokine receptor 4(CCR4) antagonists and one or more checkpoint inhibitors |
| TW202039557A (en) | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | Il2rbeta/common gamma chain antibodies |
| TW202031683A (en) | 2018-11-09 | 2020-09-01 | 新加坡商優其洛伊生物私人有限公司 | Il2rbeta/common gamma chain antibodies |
| US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| US20220064303A1 (en)* | 2018-12-27 | 2022-03-03 | Gigagen, Inc. | Anti-CTLA-4 Binding Proteins and Methods of Use Thereof |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN110343180B (en)* | 2019-07-25 | 2021-03-30 | 北京免疫方舟医药科技有限公司 | anti-CTLA-4 antibodies and uses thereof |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| US20240084011A1 (en)* | 2020-06-11 | 2024-03-14 | Nantbio, Inc. | Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors |
| CN116234821A (en)* | 2020-07-02 | 2023-06-06 | 吉加根公司 | anti-CTLA-4 binding proteins and methods of use thereof |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022169269A1 (en)* | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | Anti-ctla-4 antibody and use thereof |
| RU2757418C1 (en)* | 2021-03-04 | 2021-10-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" | Tetradecapeptide antagonist of interaction ctla-4 with b7-1 |
| KR20240005741A (en) | 2021-04-09 | 2024-01-12 | 오제 이뮈노테라프틱스 | Novel scaffolds for bifunctional molecules with improved properties |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| CN119907811A (en) | 2022-08-02 | 2025-04-29 | Ose免疫疗法公司 | Multifunctional molecules targeting CD28 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2252732T3 (en) | 1992-05-26 | 2006-05-16 | Immunex Corporation | NEW CITOQUINA THAT JOINS CD30. |
| CA2381770C (en) | 1999-08-24 | 2007-08-07 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| ITRM20010408A1 (en) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR. |
| CN1638800A (en) | 2002-01-09 | 2005-07-13 | 米德列斯公司 | Human monoclonal antibodies against CD30 |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| SI2287195T1 (en) | 2004-07-01 | 2019-08-30 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| WO2006099875A1 (en) | 2005-03-23 | 2006-09-28 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human CD134 (OX40) human monoclonal antibody and method of making and using same |
| ES2613957T3 (en) | 2006-08-04 | 2017-05-29 | Medimmune Limited | Antibodies against ERBB2 |
| EP2087114B1 (en) | 2006-11-13 | 2013-05-29 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using sirna molecules directed against cd24 |
| PL2129396T3 (en) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| WO2009073533A2 (en) | 2007-11-30 | 2009-06-11 | Medarex, Inc. | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
| HUE034832T2 (en) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| CN103068850A (en) | 2010-05-26 | 2013-04-24 | 明尼苏达大学评议会 | Single -chain variable fragment anti-cd133 antibodies and uses thereof |
| LT2609118T (en) | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| HRP20180640T1 (en) | 2011-04-25 | 2018-06-01 | Daiichi Sankyo Company, Limited | ANTI-B7-H3 ANTIBODY |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| IN2014CN03042A (en) | 2011-09-30 | 2015-07-03 | Regeneron Pharma | |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| WO2015042246A1 (en) | 2013-09-20 | 2015-03-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| PE20170254A1 (en) | 2013-12-24 | 2017-04-12 | Janssen Pharmaceutica Nv | ANTIBODIES AND ANTI-VISION FRAGMENTS |
| CN104974253A (en)* | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | Anti-CTLA-4/PD-1 bispecific antibody as well as preparation method and application thereof |
| SG10201603721TA (en)* | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| Publication number | Publication date |
|---|---|
| US9758583B2 (en) | 2017-09-12 |
| WO2017194265A1 (en) | 2017-11-16 |
| SG11201809857TA (en) | 2018-12-28 |
| KR20190015715A (en) | 2019-02-14 |
| CN109563165B (en) | 2020-09-25 |
| CN109563165A (en) | 2019-04-02 |
| CA3023787A1 (en) | 2017-11-16 |
| JP6650537B2 (en) | 2020-02-19 |
| JP2019519208A (en) | 2019-07-11 |
| US11267887B2 (en) | 2022-03-08 |
| EP3455255B1 (en) | 2021-03-03 |
| US20190153097A1 (en) | 2019-05-23 |
| TW201739763A (en) | 2017-11-16 |
| EP3455255A1 (en) | 2019-03-20 |
| AU2017262448A1 (en) | 2019-01-03 |
| US20170226211A1 (en) | 2017-08-10 |
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500002I1 (en) | Novel anti-pd-l1 antibodies | |
| ZA201900353B (en) | Anti-pd-l1 antibodies | |
| IL262295A (en) | Anti-pd-l1 antibodies | |
| IL264159A (en) | Anti-tim-3 antibodies | |
| SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
| IL255727A (en) | Novel anti-pd-l1 antibodies | |
| PL3512547T3 (en) | Anti-pd-1 antibodies | |
| SG11201705552QA (en) | Anti-pd-l1 antibodies | |
| SG10201601719RA (en) | Anti-LAG-3 Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| HUS2500024I1 (en) | Anti-pd-1 antibodies | |
| GB201610044D0 (en) | Antibodies | |
| GB201616699D0 (en) | Antibodies | |
| ZA201808317B (en) | Anti-tnfrsf25 antibodies | |
| GB201603291D0 (en) | Antibodies | |
| IL264262A (en) | Anti-il-22r antibodies | |
| GB201622197D0 (en) | Antibodies | |
| GB201620414D0 (en) | Antibodies | |
| GB201615224D0 (en) | Antibodies | |
| GB201613158D0 (en) | Antibodies | |
| GB201612437D0 (en) | Anti-lag-3 antibodies |